Over 60,000 cases were registered for participation!

Foreword

Shanghai Epiprobe Biotech Co., Ltd. and its wholly-owned subsidiary Shandong Epiprobe Biotech Medical Laboratory Co., Ltd. participate in the "Elimination of cervical cancer, Build a healthy Chinese dream" Shandong Province cervical cancer prevention large-scale public welfare project since the launch of March 5, has been accelerated without stop, and has achieved phased results. In order to further consolidate the screening results, the project will conduct follow-up work to ensure that the high-risk population screened receives continuous attention and treatment.

Project Introduction

In order to actively respond to the "Global Strategy for Accelerating the Elimination of Cervical Cancer" proposed by the World Health Organization, thoroughly implement the "Healthy China 2030" plan Outline and the "Chinese Women's Development Program (2021-2030)", accelerate the process of eliminating cervical cancer, protect and improve the health of women, "Eliminating Cervical Cancer and Building a Healthy Chinese Dream" Shandong Provincial large-scale public welfare project for the prevention of cervical cancer provides free, comprehensive and accurate cervical cancer screening services for 100,000 women of appropriate age in Shandong Province through advanced screening technology and scientific management means, and the use of HPV, cytology examination and gene methylation detection, and promotes the prevention and early treatment of cancer before it is diagnosed. We will do our best to improve women's health and well-being.

Early diagnosis and early treatment of cancer is a major strategy for healthy China. As an advocate and pioneer of whole cancer early screening, we have been deeply engaged in the field of cancer screening. Relying on the Me-qPCR technology platform, we have established the whole cancer marker TAGMe@ in vitro non-invasive detection technology based on DNA methylation, and carried out the early diagnosis and detection project of tumors. Focusing on high-incidence tumors, we have developed and stored a series of rich product pipelines, including female reproductive tract tumors (cervical cancer, endometrial cancer), urothelial cancer, blood cancer detection, lung cancer detection, prostate cancer detection, benign and malignant evaluation of serosal effusion, liposarcoma detection and evaluation.